tldrdailynews.com logo
Tag

Stock Surge

All articles tagged with #stock surge

ChargePoint rides momentum as Q2 beat powers 70% stock surge
business1 month ago

ChargePoint rides momentum as Q2 beat powers 70% stock surge

ChargePoint stock jumped over 70% after a stronger-than-expected Q2 with revenue of $116.1 million and a 35-cent loss per share, beating estimates and guiding higher for 2027. CEO Rick Wilmer says momentum is accelerating thanks to new high-performance chargers, AI-driven efficiency, and a three-year plan to cut losses and move toward EBITDA profitability. The company, which provides hardware, software, and services (not chargers themselves), is expanding Level 3 chargers in Europe and Level 2/3 in the US, while user demand remains solid despite a broader EV slowdown.

via CNBC|
#ai#business#chargepoint
GoPro pivots to AI data centers via merger, fueling a 40% stock jump
business1 month ago

GoPro pivots to AI data centers via merger, fueling a 40% stock jump

GoPro said it will merge with private photonics company Starman Optical to expand into AI data center and defense markets, in a deal that includes a $285 million cash payment ($1.14 per share) and leaves the stock Nasdaq-listed. The announcement sent GoPro shares up about 40%. Notable investors include Markiplier with an 8.5% stake and BlackRock at 6.4%. GoPro will repay $92 million of debt at closing and will continue supporting its consumer products and cloud platform while pursuing a broader imaging/optics and AI infrastructure roadmap.

via CNBC|
#ai-data-centers#business#gopro
Moderna Stock Pops 14% on Early Hantavirus Vaccine Work
market-news5 months ago

Moderna Stock Pops 14% on Early Hantavirus Vaccine Work

Moderna’s shares jumped about 14% after news of early hantavirus vaccine research with the U.S. Army and Korea University, though executives say the work is in its infancy and not close to a vaccine. Experts note funding has been limited because hantavirus outbreaks are rare, suggesting a vaccine could be years or even a decade away. Wall Street shows a Hold consensus on MRNA with a $41.75 target implying potential downside, so the stock move reflects long‑term research interest rather than near‑term product prospects.

via TipRanks|
#hantavirus#market-news#moderna
Nvidia's AI optics push gets a Corning boost
markets5 months ago

Nvidia's AI optics push gets a Corning boost

Nvidia stock rose about 4.4% midday after the company announced a deal to invest in Corning to add three new optical manufacturing plants in North Carolina and Texas, advancing its AI infrastructure push. The arrangement includes Nvidia’s option to invest up to $2.7 billion in Corning and warrants for up to 15 million Corning shares (exercise price $180) plus a pre-funded warrant for 3 million shares, continuing a string of optics-focused investments that began with earlier partnerships with Coherent and Lumentum. The move underscores Nvidia’s strategy to own more of the AI hardware supply chain as demand for faster, light-speed AI infrastructure grows.

via The Motley Fool|
#ai-infrastructure#corning#markets
Allbirds pivots to AI compute with NewBird AI, fueling a huge stock rally
business6 months ago

Allbirds pivots to AI compute with NewBird AI, fueling a huge stock rally

Allbirds says it is exiting footwear to become an AI compute company via a new entity named NewBird AI, after selling its IP/assets to American Exchange Group for $39 million two weeks earlier. NewBird AI plans to raise up to $50 million to acquire high-performance, low-latency AI hardware under long‑term leases, with a funding close expected in Q2 2026. American Exchange Group will continue to sell products under the Allbirds brand. Investors cheered the news, sending Allbirds’ shares up more than 300% in early trading and valuing the company around $20 million.

via CNBC|
#ai-compute#allbirds#american-exchange-group
ImmunityBio's Anktiva Sparks 700% Sales Leap and Global Approvals
market-news9 months ago

ImmunityBio's Anktiva Sparks 700% Sales Leap and Global Approvals

ImmunityBio (IBRX) stock jumped over 30% after 2025 preliminary results showed Anktiva sales up about 700% year-over-year to roughly $113 million, with Q4 2025 revenue up 431% to $38.3 million. Regulatory wins expanding Anktiva’s reach include Saudi approvals for NSCLC combinations and for bladder cancer with BCG, while Phase 2b enrollment for first-line bladder cancer is progressing. Analysts sketch a bullish picture with a Strong Buy rating and a roughly $7.33 price target, implying substantial upside potential.

via TipRanks|
#anktiva#biotech#ibrx